# The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI

> **NCT02835534** · PHASE4 · COMPLETED · sponsor: **CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.** · enrollment: 818 (actual)

## Conditions studied

- Acute ST Elevation Myocardial Infarction

## Interventions

- **DRUG:** rhTNK-tPA
- **DRUG:** alteplase

## Key facts

- **NCT ID:** NCT02835534
- **Lead sponsor:** CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2019-10
- **Final completion:** 2020-01
- **Target enrollment:** 818 (ACTUAL)
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02835534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02835534, "The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02835534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*